HALO (Halozyme Therapeutics) Probability of Financial Distress (%): 0.03% (As of Jun. 28, 2026)


HALO Halozyme Therapeutics Inc HALO
92 GF Score
Price $74.96
GF Value $90.32
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Probability of Financial Distress (%)?

Halozyme Therapeutics HALO +3.19% 92 Probability of Financial Distress (%) is 0.03% as of Jun. 28, 2026. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.32 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Halozyme Therapeutics's Probability of Financial Distress (%) is 0.03%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.

Halozyme Therapeutics  (NAS:HALO) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.

Halozyme Therapeutics Probability of Financial Distress (%) Related Terms

HALO vs IBRX, TECH, CORT: Probability of Financial Distress (%) Comparison

For the Biotechnology subindustry, Halozyme Therapeutics's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics Probability of Financial Distress (%) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Probability of Financial Distress (%) falls into.


HALO
92GF Score
Halozyme Therapeutics Inc HALO
Probability of Financial Distress (%) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-8.00

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.03%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio

MB=Market Cap / Adjusted Book Equity
=Market Cap / (Total Stockholders Equity + 0.1 * ( Market Cap - Total Stockholders Equity))

8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).

What does a Probability of Financial Distress (%) of 0.03% mean?
Halozyme Therapeutics (HALO) has a Probability of Financial Distress (%) of 0.03% as of Jun. 28, 2026.
Is Halozyme Therapeutics' Probability of Financial Distress (%) too high?
Halozyme Therapeutics' current Probability of Financial Distress (%) is 0.03%. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Probability of Financial Distress (%) compare to IBRX and TECH?
Halozyme Therapeutics' Probability of Financial Distress (%) of 0.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Probability of Financial Distress (%) for a Biotechnology company?
A good Probability of Financial Distress (%) depends on the Biotechnology industry context. However, Probability of Financial Distress (%) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Probability of Financial Distress (%) mean?
A high Probability of Financial Distress (%) can signal that a stock is expensive relative to its fundamentals. Halozyme Therapeutics's current Probability of Financial Distress (%) is 0.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.32, compared to a current price of $74.96 — trading 17% below its estimated fair value. The current Probability of Financial Distress (%) is 0.03%. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Probability of Financial Distress (%) calculated?
Probability of Financial Distress (%) is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Probability of Financial Distress (%) is 0.03% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $74.96 is trading 17% below its estimated GF Value™ of $90.32. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

  • Probability of Financial Distress (%): 0.03%
  • GF Value™: $90.32 vs. price of $74.96 (17% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score

Get the complete analysis for HALO

Probability of Financial Distress (%) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$74.96
Price
$90.32
GF Value